Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2015 · 10-K
Revenue$79.00K$79.00K+41.1% vs Q4 2014 Net Income-$7.38M-$7.38MderivedN/M vs Q4 2014 EPS Diluted-$0.26-$0.26N/M vs Q4 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
-$7,384,141
N/M
Operating Cash Flowderived-$6,808,936N/M Free Cash Flowderived-$7,793,014N/M Margins · derivedOperating margin-9347.0%−1304.7 pt vs Q4 2014
Net margin-9342.8%−979.7 pt vs Q4 2014
ended Dec 31, 2015 · filed Mar 10, 2016 · 70 d after period end